These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12667890)

  • 1. Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future.
    Aihara T; Nakamura E; Amagase K; Tomita K; Fujishita T; Furutani K; Okabe S
    Pharmacol Ther; 2003 Apr; 98(1):109-27. PubMed ID: 12667890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New molecular targets for treatment of peptic ulcer disease.
    Lehmann F; Hildebrand P; Beglinger C
    Drugs; 2003; 63(17):1785-97. PubMed ID: 12921485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complexity of gastric acid secretion revealed by targeted gene disruption in mice.
    Chen D; Zhao CM
    Curr Pharm Des; 2010; 16(10):1235-40. PubMed ID: 20166994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of gastric acid secretion and therapeutic results: is there any correlation?
    Corinaldesi R; Ghidini C; Ricci Maccarini M; Santaguida P; Fratesi E; Barbara G; Stanghellini V
    Ital J Gastroenterol; 1990; 22 Suppl 1():2-4. PubMed ID: 1983421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acid secretion and suppression.
    Katz J
    Med Clin North Am; 1991 Jul; 75(4):877-87. PubMed ID: 2072793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is smoking still important in the pathogenesis of peptic ulcer disease?
    Eastwood GL
    J Clin Gastroenterol; 1997; 25 Suppl 1():S1-7. PubMed ID: 9479620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Optimal use of acid-inhibitors in acid-related diseases. Physiological and physiopathological considerations with implications on therapeutic choice].
    Waldum HL
    Tidsskr Nor Laegeforen; 1993 Feb; 113(4):465-9. PubMed ID: 8465291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs for treatment of peptic ulcers.
    Dajani EZ; Trotman BW
    J Assoc Acad Minor Phys; 1992; 3(3):78-88. PubMed ID: 1353999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase.
    McArthur KE; Jensen RT; Gardner JD
    Annu Rev Med; 1986; 37():97-105. PubMed ID: 3010811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton-pump inhibitors for gastric acid-related disease.
    Franko TG; Richter JE
    Cleve Clin J Med; 1998 Jan; 65(1):27-34. PubMed ID: 9465453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of antisecretory and antiulcer activity of CR 2945, a new potent and selective gastrin/CCK(B) receptor antagonist.
    Makovec F; Revel L; Letari O; Mennuni L; Impicciatore M
    Eur J Pharmacol; 1999 Mar; 369(1):81-90. PubMed ID: 10204685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisecretory and mucosal protective actions of misoprostol. Potential role in the treatment of peptic ulcer disease.
    Wilson DE
    Am J Med; 1987 Jul; 83(1A):2-8. PubMed ID: 3113241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors.
    Shamburek RD; Schubert ML
    Gastroenterol Clin North Am; 1992 Sep; 21(3):527-50. PubMed ID: 1355465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The changing role of H2-receptor antagonists in acid-related diseases.
    Lamers CB
    Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S3-7. PubMed ID: 8930573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological and therapeutic properties of lafutidine (stogar and protecadin), a novel histamine H2 receptor antagonist with gastroprotective activity].
    Tanaka M; Banba M; Joko A; Moriyama Y
    Nihon Yakurigaku Zasshi; 2001 Jun; 117(6):377-86. PubMed ID: 11436515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helicobacter pylori and its involvement in gastritis and peptic ulcer formation.
    Konturek SJ; Konturek PC; Konturek JW; Plonka M; Czesnikiewicz-Guzik M; Brzozowski T; Bielanski W
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():29-50. PubMed ID: 17033104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptic ulcer disease: physiology and pathophysiology.
    Holt KM; Isenberg JI
    Hosp Pract (Off Ed); 1985 Jan; 20(1):89-93, 96-101, 104-6. PubMed ID: 2856923
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis and therapy of peptic ulcer disease.
    Peterson WL
    J Clin Gastroenterol; 1990; 12 Suppl 2():S1-6. PubMed ID: 1978840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.